Statistics from Altmetric.com
Multicentre randomised controlled trial.
Follow up period:
Six weeks (treatment period only).
Seventy six centres (52 primary care centres and 24 psychiatric centres) in five European countries, 1999–2001.
426 adults with DSM-IV generalised anxiety disorder (GAD; diagnosed using the Mini-International Neuropsychiatric Interview) with predominantly symptoms of anxiety rather than depression (Covi Anxiety Scale score ⩾9 and Raskin Depression Scale score ⩽7) and Hamilton Rating Scale for Anxiety (HAM-A) score ⩾20. Main exclusions: current Axis I disorders (except simple phobia, somatisation disorder, dysthymia, or depression not otherwise …
For correspondence: Stuart A Montgomery, MD, PhD, PO Box 8751, London W13 8WH, UK;
Source of funding: Pfizer Inc, New York, NY, USA.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.